Tandem Diabetes Ownership
| TNDM Stock | USD 30.81 0.07 0.23% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 65 M | Current Value 66 M | Avarage Shares Outstanding 38.8 M | Quarterly Volatility 28.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tandem |
Tandem Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 494.25. Tandem Diabetes Care recorded a loss per share of 1.94. The entity last dividend was issued on the 10th of October 2017. The firm had 1:10 split on the 10th of October 2017. Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. To find out more about Tandem Diabetes Care contact the company at 858 366 6900 or learn more at https://www.tandemdiabetes.com.Besides selling stocks to institutional investors, Tandem Diabetes also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tandem Diabetes' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tandem Diabetes' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tandem Diabetes Quarterly Liabilities And Stockholders Equity |
|
Tandem Diabetes Insider Trades History
Less than 1% of Tandem Diabetes Care are currently held by insiders. Unlike Tandem Diabetes' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tandem Diabetes' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tandem Diabetes' insider trades
Tandem Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tandem Diabetes is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tandem Diabetes Care backward and forwards among themselves. Tandem Diabetes' institutional investor refers to the entity that pools money to purchase Tandem Diabetes' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ameriprise Financial Inc | 2024-06-30 | 1.5 M | Champlain Investment Partners, Llc | 2024-09-30 | 1.5 M | Hhg Plc | 2024-06-30 | 1.5 M | Stephens Inv Mgmt Group Llc | 2024-09-30 | 1.3 M | Two Sigma Advisers, Llc | 2024-06-30 | 1.1 M | Park West Asset Management Llc | 2024-09-30 | 1.1 M | Millennium Management Llc | 2024-06-30 | 1.1 M | Divisadero Street Capital Management, Lp | 2024-09-30 | 1.1 M | First Light Asset Management, Llc | 2024-09-30 | 1 M | Blackrock Inc | 2024-06-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 7.4 M |
Tandem Diabetes Care Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tandem Diabetes insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tandem Diabetes' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tandem Diabetes insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tandem Diabetes' latest congressional trading
Congressional trading in companies like Tandem Diabetes Care, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Tandem Diabetes by those in governmental positions are based on the same information available to the general public.
| 2024-09-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Tandem Diabetes Outstanding Bonds
Tandem Diabetes issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tandem Diabetes Care uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tandem bonds can be classified according to their maturity, which is the date when Tandem Diabetes Care has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Tandem Diabetes Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 26th of June 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.